230 filings
Page 6 of 12
8-K
otk6rsrdb
12 Aug 21
Motus GI Reports Second Quarter 2021 Financial Results and Provides Corporate Update
4:10pm
8-K
84b opwotr12v
21 Jul 21
Motus GI Secures Expanded $12M Credit Financing to Support Growth Strategy
8:06am
DEFA14A
ti8gx jl3
2 Jul 21
Additional proxy soliciting materials
4:17pm
8-K
7va4lr2q70u
23 Jun 21
Motus GI Appoints Experienced Financial Biotech Executive, Sonja Nelson, to its Board of Directors and as Chair of Audit Committee
4:10pm
8-K
jhsc650ik aibj0io3g4
16 Jun 21
Motus GI Announces First Patients Enrolled in the European Union Feasibility Study
8:05am
8-K
1gxjtldpfe5m5
3 Jun 21
Motus GI Announces Publication of Pure-Vu® System Clinical Data
8:11am
8-K
5pba02y smnbw
25 May 21
Implementation of the Pure-Vu System is designed to improve efficiencies and outcomes
8:05am
8-K
r0w3 7yeu0jm7mdgrc
13 May 21
Motus GI Reports First Quarter 2021 Financial Results and Provides Corporate Update
4:10pm
8-K
6wmr60rjuje aohynk
7 May 21
Motus GI Announces Publication of a Pure-Vu System® Cost Effectiveness Analysis in the Journal of Cost Effectiveness and Resource Allocation
7:37am
8-K
ibabvy7kri9 djgfthlb
30 Apr 21
Motus GI Receives FDA Clearance to Market the Pure-Vu® System for Upper GI Endoscopy
10:45am
EFFECT
i53 51tpap5w1
29 Mar 21
Notice of effectiveness
12:15am
EFFECT
7e4d0kmq
29 Mar 21
Notice of effectiveness
12:15am
424B3
ebs27p2s1gl
26 Mar 21
Prospectus supplement
4:43pm
424B5
5czh5gekyl9gu7m
26 Mar 21
Prospectus supplement for primary offering
4:41pm
CORRESP
slmgep5l7sl7rq9kzvt
24 Mar 21
Correspondence with SEC
12:00am
CORRESP
mj7dsvhvuc
24 Mar 21
Correspondence with SEC
12:00am
UPLOAD
0uph t8u8u
23 Mar 21
Letter from SEC
12:00am